{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:09:33Z","timestamp":1792130973459,"version":"4.4.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jns.2015.02.019","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T07:45:17Z","timestamp":1424159117000},"page":"174-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis"],"prefix":"10.1016","volume":"351","author":[{"given":"Robert C.","family":"Sergott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mikol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Freudensprung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Plitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 2","key":"10.1016\/j.jns.2015.02.019_bb0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/brain\/awr264","article-title":"Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis","volume":"135","author":"Syc","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.jns.2015.02.019_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2006.06.032","article-title":"Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment","volume":"180","author":"Antel","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2015.02.019_bb0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ana.20152","article-title":"B-lymphocyte and plasma cell clonal expansion in monosymptomatic optic neuritis cerebrospinal fluid","volume":"56","author":"Haubold","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2015.02.019_bb0020","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2015.02.019_bb0025","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/art.30373","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jns.2015.02.019_bb0030","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/art.30372","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial","volume":"63","author":"van Vollenhoven","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jns.2015.02.019_bb0035","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythmatosus (SLE): 52-week data (APRIL-SLE randomised trial)","author":"Isenberg","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jns.2015.02.019_bb0040","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"issue":"Suppl.","key":"10.1016\/j.jns.2015.02.019_bb0045","first-page":"S180","article-title":"ATON: results from a randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis","volume":"17","author":"Sergott","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2015.02.019_bb0050","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2015.02.019_bb0055","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/brain\/awq146","article-title":"A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials","volume":"133","author":"Henderson","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jns.2015.02.019_bb0060","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1093\/brain\/awh284","article-title":"A serial MRI study following optic nerve mean area in acute optic neuritis","volume":"127","author":"Hickman","year":"2004","journal-title":"Brain"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X15000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T05:27:20Z","timestamp":1537853240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X15000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":12,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0022510X15000866"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2015.02.019","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2015.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}